Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Exclusion Criteria

• •Use of any investigational or non-registered drug or vaccine other than the study vaccine (s) during the study period or within 30 days preceding the first dose of study vaccine.
• •Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after.
• •Previous vaccination against hepatitis B.
• •History of non-response to previous hepatitis B vaccination.
• •Known exposure to hepatitis B within the past 6 weeks.
• •History of hepatitis B infection.
• •Confirmed human immunodeficiency virus (HIV) infection.
• •A family history of congenital or hereditary immunodeficiency.
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• •Acute disease at the time of enrollment.
• •Hepatomegaly, right upper quadrant abdominal pain or tenderness.
• •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration/ administration during the study period.
• •Pregnant or lactating female